ARTICLE | Company News
OSI submits Tarceva sNDA
May 3, 2005 1:20 AM UTC
Genentech (DNA) said partner OSIP submitted an sNDA to FDA for Tarceva erlotinib plus gemcitabine to treat first-line advanced pancreatic cancer. The sNDA is based on a Phase III trial evaluating Tarc...